These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37435448)

  • 1. Molecular mechanisms involved in somatostatin receptor regulation in corticotroph tumors: the role of cytoskeleton and USP8 mutations.
    Peverelli E; Treppiedi D; Mantovani G
    Endocr Oncol; 2022 Jan; 2(1):R24-R30. PubMed ID: 37435448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved pasireotide response in USP8 mutant corticotroph tumours in vitro.
    Albani A; Perez-Rivas LG; Tang S; Simon J; Lucia KE; Colón-Bolea P; Schopohl J; Roeber S; Buchfelder M; Rotermund R; Flitsch J; Thorsteinsdottir J; Herms J; Stalla G; Reincke M; Theodoropoulou M
    Endocr Relat Cancer; 2022 Aug; 29(8):503-511. PubMed ID: 35686696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators.
    Mallick S; Chakrabarti J; Eschbacher J; Moraitis AG; Greenstein AE; Churko J; Pond KW; Livolsi A; Thorne CA; Little AS; Yuen KCJ; Zavros Y
    Transl Res; 2023 Jun; 256():56-72. PubMed ID: 36640905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease.
    Hayashi K; Inoshita N; Kawaguchi K; Ibrahim Ardisasmita A; Suzuki H; Fukuhara N; Okada M; Nishioka H; Takeuchi Y; Komada M; Takeshita A; Yamada S
    Eur J Endocrinol; 2016 Feb; 174(2):213-26. PubMed ID: 26578638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs.
    Treppiedi D; Marra G; Di Muro G; Esposito E; Barbieri AM; Catalano R; Mangili F; Bravi F; Locatelli M; Lania AG; Ferrante E; Indirli R; Nozza E; Arlati F; Spada A; Arosio M; Mantovani G; Peverelli E
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
    Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
    Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant.
    Pivonello R; Munster PN; Terzolo M; Ferrigno R; Simeoli C; Puglisi S; Bali U; Moraitis AG
    Front Endocrinol (Lausanne); 2021; 12():793262. PubMed ID: 35058882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing's disease and silent corticotroph tumors.
    Kober P; Rusetska N; Mossakowska BJ; Maksymowicz M; Pękul M; Zieliński G; Styk A; Kunicki J; Działach Ł; Witek P; Bujko M
    Front Endocrinol (Lausanne); 2023; 14():1124646. PubMed ID: 37065760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs.
    Treppiedi D; Di Muro G; Marra G; Barbieri AM; Mangili F; Catalano R; Serban A; Ferrante E; Locatelli M; Lania AG; Arosio M; Spada A; Peverelli E; Mantovani G
    Endocr Relat Cancer; 2021 Jun; 28(8):573-582. PubMed ID: 34086599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells.
    Treppiedi D; Di Muro G; Mangili F; Catalano R; Giardino E; Barbieri AM; Locatelli M; Arosio M; Spada A; Peverelli E; Mantovani G
    Mol Cell Endocrinol; 2021 Mar; 524():111159. PubMed ID: 33428965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression.
    Mizuno T; Inoshita N; Fukuhara N; Tatsushima K; Takeshita A; Yamada S; Nishioka H; Takeuchi Y
    Intern Med; 2022 Mar; 61(5):679-685. PubMed ID: 34471015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein expression of somatostatin receptor 2, somatostatin receptor 5 and dopamine D2 receptor in normal pituitary gland and ACTH-secreting pituitary adenoma in dogs.
    Sato A; Hara Y
    Res Vet Sci; 2018 Aug; 119():61-66. PubMed ID: 29864631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas.
    Cuevas-Ramos D; Fleseriu M
    J Mol Endocrinol; 2014 Jun; 52(3):R223-40. PubMed ID: 24647046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of β-arrestin1 and β-arrestin2 on somatostatin receptors in murine AtT-20 corticotroph tumor cells.
    Kageyama K; Hagiwara R; Niioka K; Takayasu S; Daimon M
    Endocr J; 2021 Feb; 68(2):163-170. PubMed ID: 32963176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas.
    Tateno T; Kato M; Tani Y; Oyama K; Yamada S; Hirata Y
    Endocr J; 2009; 56(4):579-84. PubMed ID: 19318729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent gain-of-function USP8 mutations in Cushing's disease.
    Ma ZY; Song ZJ; Chen JH; Wang YF; Li SQ; Zhou LF; Mao Y; Li YM; Hu RG; Zhang ZY; Ye HY; Shen M; Shou XF; Li ZQ; Peng H; Wang QZ; Zhou DZ; Qin XL; Ji J; Zheng J; Chen H; Wang Y; Geng DY; Tang WJ; Fu CW; Shi ZF; Zhang YC; Ye Z; He WQ; Zhang QL; Tang QS; Xie R; Shen JW; Wen ZJ; Zhou J; Wang T; Huang S; Qiu HJ; Qiao ND; Zhang Y; Pan L; Bao WM; Liu YC; Huang CX; Shi YY; Zhao Y
    Cell Res; 2015 Mar; 25(3):306-17. PubMed ID: 25675982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of somatostatin analogs in Cushing's disease.
    van der Hoek J; Lamberts SW; Hofland LJ
    Pituitary; 2004; 7(4):257-64. PubMed ID: 16132202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Profiling of a Cohort of Italian Patients with ACTH-Secreting Pituitary Tumors and Characterization of a Novel
    Treppiedi D; Barbieri AM; Di Muro G; Marra G; Mangili F; Catalano R; Esposito E; Ferrante E; Serban AL; Locatelli M; Lania AG; Spada A; Arosio M; Peverelli E; Mantovani G
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of Ubiquitin Specific Protease 8 (USP8) Mutations in Canine Corticotroph Pituitary Adenomas.
    Sbiera S; Tryfonidou MA; Weigand I; Grinwis GC; Broeckx B; Herterich S; Allolio B; Deutschbein T; Fassnacht M; Meij BP
    PLoS One; 2016; 11(12):e0169009. PubMed ID: 28005997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic
    Pérez-Rivas LG; Theodoropoulou M; Puar TH; Fazel J; Stieg MR; Ferraù F; Assié G; Gadelha MR; Deutschbein T; Fragoso MC; Kusters B; Saeger W; Honegger J; Buchfelder M; Korbonits M; Bertherat J; Stalla GK; Hermus AR; Beuschlein F; Reincke M
    Eur J Endocrinol; 2018 Jan; 178(1):57-63. PubMed ID: 28982703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.